Progressive Multifocal Leukoencephalopathy (PML)
Plasma exchange and steroids should be used with caution in patients with PML.
Improving PML risk estimates is an important component of treatment with natalizumab for multiple sclerosis.
The biannual infusion is approved for the treatment of adults with relapsing and progressive forms of multiple sclerosis.
Over 90% of participants achieved NEDA-3 after being transitioned to dimethyl-fumarate from natalizumab.
The clarity of "punctate patterns" on MRI increased with disease severity, with nonenhancing lesions more evident in earlier stages of progressive multifocal leukoencephalopathy.
Neurology Advisor Articles
- Addressing Rare Headache Disorders: Acute Confusional Migraine
- Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis
- No Significant Clinical Differences Between Cluster Headaches With and Without Aura
- Co-Prescription of Opioids and Antidepressants Prevalent in Migraine
- Deep Brain Stimulation May Slow Rest Tremor Progression in Parkinson Disease
- Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds
- Patients' Preferences for Physician Attire Linked to Perception of Care
- Weighing the Risks of Deep Brain Stimulation
- Grey Matter Atrophy Sequence in Multiple Sclerosis Phenotypes
- Higher Vitamin D Levels Associated With Fewer Lesions in Multiple Sclerosis
- Screening Tool Differentiates Progressive Supranuclear Palsy and Parkinson Disease
- Risk Factors for Impulse Control Behaviors in Parkinson Disease
- Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths
- 11.2% of U.S. Adults Aged ≥45 Report Subjective Mental Decline
- AMA Aims to Boost Affordability of ACA Marketplace Plans